Teva Pharm Stock Price, News & Analysis

Teva Pharmaceuticals announced new data on AJOVY and AUSTEDO, showcasing their safety and efficacy at the American Academy of Neurology Annual Meeting from April 2-7, 2022. The research highlights include 11 abstracts on AJOVY for migraine treatment, focusing on its effectiveness across various patient demographics. Furthermore, AUSTEDO's long-term analyses for tardive dyskinesia were presented, revealing insights on treatment outcomes. Teva aims to enhance understanding of these therapies while supporting the healthcare community's knowledge.

Teva Pharmaceuticals has reached a settlement with Florida's Attorney General, resolving opioid-related claims. The agreement includes payments totaling $177 million over 15 years and provides generic Narcan (naloxone hydrochloride) valued at $84 million over 10 years. This resolution aims to assist those suffering from opioid addiction and does not imply any admission of liability by Teva. The company will maintain its defense in ongoing litigations in states without settlements.

Teva Pharmaceuticals has reached a settlement with Rhode Island's Attorney General concerning opioid-related claims, agreeing to pay $21 million over 13 years. Additionally, Teva will provide generic Narcan and Suboxone, valued at $78.5 million, over 10 years. This settlement is seen as a step towards addressing the opioid crisis and does not imply any admission of wrongdoing. Teva continues to pursue a national settlement, while stating that the agreement will help distribute life-saving treatments effectively in Rhode Island.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has launched the first generic version of Revlimid® (lenalidomide capsules) in the U.S., available in 5mg, 10mg, 15mg, and 25mg strengths. This launch provides vital treatment options for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. With an annual sales figure of $2.3 billion for Revlimid® as of December 2021, Teva's entry into this market strengthens its portfolio, which includes nearly 550 FDA-approved generic medicines, thus solidifying its status as a leader in the generics sector.

Teva Pharmaceuticals announces an update to the Summary of Product Characteristics for COPAXONE® (Glatiramer Acetate) in Europe, now approved for use in breastfeeding. This decision follows the COBRA study, which examined the effects on infants breastfed by mothers on GA treatment. The study involved 120 infants and found no adverse effects related to maternal GA exposure during breastfeeding. The update emphasizes the positive benefit/risk balance for MS patients wishing to breastfeed while receiving treatment.

Teva Pharmaceutical Industries Ltd. reported Q4 2021 revenues of $4.1 billion and full-year revenues of $15.9 billion, both showing declines from the previous year. Q4 GAAP diluted EPS was $(0.14), while non-GAAP diluted EPS rose to $0.77. For 2022, Teva forecasts revenues between $15.6 billion and $16.2 billion, with expected non-GAAP EPS of $2.40 - $2.60. The company anticipates growth from key products AUSTEDO® and AJOVY® and aims to advance FDA approval for Risperidone LAI, while resolving opioid litigation in Texas.

Teva Pharmaceuticals has settled opioid-related claims with the Texas Attorney General, agreeing to pay $150 million over 15 years and provide $75 million worth of generic Narcan over 10 years. While Teva admits no wrongdoing, CEO Kåre Schultz emphasizes the importance of expanding access to life-saving medications. The deal is seen as a crucial step in addressing the opioid crisis, although Teva will continue to defend itself in ongoing litigation in other states.

Teva Pharmaceuticals, in collaboration with Morehouse School of Medicine, released a national survey highlighting significant healthcare access challenges exacerbated by the COVID-19 pandemic. The survey indicates that 50% of consumers postponed or canceled healthcare services, with 64% of BIPOC groups affected. The report notes a rise in mental health diagnoses, with 84% of physicians observing increases since the pandemic. While 58% of consumers are likely to use telehealth post-pandemic, access remains a concern, particularly for low-income patients.